AstraZeneca PLC (AZN)vsThe Cooper Companies, Inc (COO)
AZN
AstraZeneca PLC
$161.07
+0.88%
HEALTHCARE · Cap: $263.09B
COO
The Cooper Companies, Inc
$74.23
+1.24%
HEALTHCARE · Cap: $13.71B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1350% more annual revenue ($61.37B vs $4.23B). AZN leads profitability with a 17.0% profit margin vs 5.6%. COO appears more attractively valued with a PEG of 0.69. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
COO
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.07
$35.86 discount
Margin of Safety
+59.9%
Fair Value
$206.89
Current Price
$74.23
$132.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 26.9% YoY
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
ROE of 2.9% — below average capital efficiency
5.6% margin — thin
Premium valuation, high expectations priced in
Operating margin of -2.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : COO
The strongest argument for COO centers on Debt/Equity, PEG Ratio, Price/Book. PEG of 0.69 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : COO
The primary concerns for COO are Return on Equity, Profit Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while COO is a value play — different risk/reward profiles.
COO carries more volatility with a beta of 0.84 — expect wider price swings.
COO is growing revenue faster at 7.9% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 59/100), backed by strong 17.0% margins. COO offers better value entry with a 59.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
The Cooper Companies, Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?